Comparative Pharmacology
Head-to-head clinical analysis: LUCENTIS versus MVASI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUCENTIS versus MVASI.
LUCENTIS vs MVASI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds to and inhibits the biological activity of vascular endothelial growth factor A (VEGF-A), thereby preventing VEGF-A from interacting with its receptors (VEGFR1 and VEGFR2) on endothelial cells, reducing neovascularization and vascular permeability.
Monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), preventing binding to VEGFR-1 and VEGFR-2, thereby inhibiting angiogenesis and tumor growth.
Intravitreal injection of 0.5 mg (0.05 mL) once every 4 weeks (monthly).
5 mg/kg intravenously every 2 weeks for metastatic colorectal cancer; 15 mg/kg intravenously every 3 weeks for non-small cell lung cancer, glioblastoma, renal cell carcinoma, and cervical cancer.
None Documented
None Documented
Terminal elimination half-life from vitreous humor: approximately 9 days (range 7–11 days) in humans. From serum: ~0.5 days (due to rapid systemic clearance). Clinical context: supports monthly intravitreal dosing.
Approximately 20 days (range 11–50 days); typical dosing interval every 2–3 weeks.
Primarily metabolized via catabolism to small peptides and amino acids; renal excretion of intact drug is negligible due to high molecular weight (48 kDa). Fecal/biliary elimination not characterized. Systemic clearance ~0.81 mL/hr.
Primarily metabolized via reticuloendothelial system; no significant renal or biliary excretion of intact drug.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor